Paul Garofolo

Paul Garofolo, CEO of Locus Bio, discusses the problem of antibiotic-resistant bacteria and the potential of CRISPR-Cas system as an alternative to antibiotics in combating multi-drug resistance. They explore the applications of CRISPR in gene modification, agriculture, and global competition in genetic editing technology. The significance of diverse intestinal bacteria in preventing pathogenic threats and the potential of manipulating bacteria for understanding their link to the human body and brain are also discussed.